BACKGROUND: Nucleophosmin (NPM1) gene mutations are reported to predict a favorable prognosis in acute myeloid leukemia (AML) patients. Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation. METHODS: Using immunohistochemical (IHC) analysis, we assessed for NPM (clone 376) expression in formalin-fixed, formic acid-decalcified bone marrow biopsy specimens. DNA sequencing of exon 12 of NPM1 gene was performed in 104 patients. RESULTS: The study included 252 AML patients: 192 de novo AML, 33 AML preceded by either myelodysplastic syndrome or chronic myelomonocytic leukemia, and 27 therapy-related AML. The median age was 62 years and 115 patients were <or=60 years old. All patients received intensive chemotherapy. Cytoplasmic NPM was detected in 59 of 252 (23%) patients, including 48 of 192 (25%) de novo AML and 33 of 94 (35%) with a normal karyotype. DNA sequencing identified NPM1 mutations in 30 of 38 cases with cytoplasmic NPM and 10 of 66 cases with nuclear NPM. Cytoplasmic NPM was associated with young patient age (P=.024), FLT3/ITD (P=.005), CD34 negative blasts (P<.001), high peripheral blood blast count (P=.041), and high serum albumin level (P=.028). No statistical differences in overall or event-free survival were found on the basis of NPM localization. Similar results were obtained in patients<or=60 years old with normal karyotype and wild-type FLT3 (P=.768). CONCLUSIONS: IHC assessment for NPM localization did not predict prognosis in this patient cohort. The discordance between immunohistochemistry and DNA sequencing results indicates that DNA sequencing cannot be replaced by IHC assessment. Copyright (c) 2009 American Cancer Society.
BACKGROUND:Nucleophosmin (NPM1) gene mutations are reported to predict a favorable prognosis in acute myeloid leukemia (AML) patients. Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation. METHODS: Using immunohistochemical (IHC) analysis, we assessed for NPM (clone 376) expression in formalin-fixed, formic acid-decalcified bone marrow biopsy specimens. DNA sequencing of exon 12 of NPM1 gene was performed in 104 patients. RESULTS: The study included 252 AMLpatients: 192 de novo AML, 33 AML preceded by either myelodysplastic syndrome or chronic myelomonocytic leukemia, and 27 therapy-related AML. The median age was 62 years and 115 patients were <or=60 years old. All patients received intensive chemotherapy. Cytoplasmic NPM was detected in 59 of 252 (23%) patients, including 48 of 192 (25%) de novo AML and 33 of 94 (35%) with a normal karyotype. DNA sequencing identified NPM1 mutations in 30 of 38 cases with cytoplasmic NPM and 10 of 66 cases with nuclear NPM. Cytoplasmic NPM was associated with young patient age (P=.024), FLT3/ITD (P=.005), CD34 negative blasts (P<.001), high peripheral blood blast count (P=.041), and high serum albumin level (P=.028). No statistical differences in overall or event-free survival were found on the basis of NPM localization. Similar results were obtained in patients<or=60 years old with normal karyotype and wild-type FLT3 (P=.768). CONCLUSIONS: IHC assessment for NPM localization did not predict prognosis in this patient cohort. The discordance between immunohistochemistry and DNA sequencing results indicates that DNA sequencing cannot be replaced by IHC assessment. Copyright (c) 2009 American Cancer Society.
Authors: Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner Journal: Blood Date: 2005-07-28 Impact factor: 22.113
Authors: Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner Journal: N Engl J Med Date: 2008-05-01 Impact factor: 91.245
Authors: J L Cordell; K A Pulford; B Bigerna; G Roncador; A Banham; E Colombo; P G Pelicci; D Y Mason; B Falini Journal: Blood Date: 1999-01-15 Impact factor: 22.113
Authors: Carolien M Woolthuis; André B Mulder; Rikst Nynke Verkaik-Schakel; Stefano Rosati; Arjan Diepstra; Eva van den Berg; Jan Jacob Schuringa; Edo Vellenga; Philip M Kluin; Gerwin Huls Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941
Authors: Stefan Faderl; Carlos Bueso-Ramos; Zhiming Liu; Ashutosh Pal; William Bornmann; Diana V Ciurea; David Harris; Inbal Hazan-Halevy; Hagop M Kantarjian; Zeev Estrov Journal: Invest New Drugs Date: 2010-06-03 Impact factor: 3.850
Authors: Manogna Das Oravakandy; Faiq Ahmed; Rachna Khera; Manasi Mundada; Sudha S Murthy; Senthil J Rajappa; M V T Krishna Mohan; B Pavan Kumar; A Santa Journal: Indian J Hematol Blood Transfus Date: 2022-02-01 Impact factor: 0.915
Authors: Aziz Nazha; Carlos Bueso-Ramos; Eli Estey; Stefan Faderl; Susan O'Brien; Michael H Fernandez; Martin Nguyen; Charles Koller; Emil Freireich; Miloslav Beran; Sherry Pierce; Michael Keating; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi Journal: Front Oncol Date: 2013-09-06 Impact factor: 6.244